A 2026 medical journal article, which presented some semaglutide deep vein thrombosis case information, is of interest to us because Ozempic, Wegovy, and Rybelsus — three relatively new semaglutide-containing drugs — have been associated with a significantly increased risk of blood clots. We have been investigating Ozempic, Wegovy, and Rybelsus blood clots, deep vein thrombosis (DVT), and pulmonary embolism (PE) cases as possible drug injury lawsuits against the pharmaceutical company Novo Nordisk.
In the relevant part from that medical journal article, “Deep Venous Thrombosis Within Two Weeks of Initiating Oral Semaglutide (Rybelsus): A Case Report”, we get some semaglutide deep vein thrombosis case information:
We report the case of a 16-year-old male with mild conventional risk factors for thrombosis [overweight body mass index (BMI) and prolonged sedentary behavior] who developed acute left lower extremity deep venous thrombosis (DVT) within two weeks of initiating oral semaglutide (Rybelsus, 7 mg daily) for weight reduction without medical supervision. He presented with progressive leg pain and swelling, and duplex ultrasonography revealed thrombosis of the distal superficial femoral and popliteal veins….
This case suggests a possible association between oral semaglutide and venous thrombosis in an adolescent, highlighting the need for careful supervision during off-label use.
On our Drug Injury Watch website, back in February 2024, we published this blog post, “‘New’ Blood Clots Side Effect of Semaglutide Weight Loss Drugs Like Ozempic: Deep Vein Thrombosis“, that provided some semaglutide deep vein thrombosis case information
More recently, on that same website, we have written about drug injury lawsuits involving deep vein thrombosis (DVT) associated with semaglutide-containing drugs:
- No Warnings About Blood Clots From Ozempic, Wegovy, and Rybelsus in Drug Labels (7/18/24)
- Wegovy, Rybelsus, and Ozempic Blood Clots Cases Are Not Part of Federal Court MDL at This Time (5/14/24)
We can assist individuals with a semaglutide deep vein thrombosis case if they submit an online Case Evaluation Form or call us at 910-256-2971.
Ozempic / Rybelsus / Wegovy
Free Case Evaluation
Strictly Confidential, No Obligation